ProKidney (NASDAQ: PROK) is a late-clinical-stage biotechnology company pioneering a novel autologous cell therapy designed to preserve kidney function in patients with advanced chronic kidney disease (CKD) at high risk of kidney failure, a population with limited treatment options beyond preparing for dialysis or kidney transplant.
ProKidney is redefining what’s possible in the treatment of chronic kidney disease. Leveraging deep scientific leadership in autologous cell therapy, we are advancing a first of its kind, personalized therapeutic approach designed to help preserve kidney function and delay the need for dialysis. As the only company developing an autologous cell therapy specifically for people with advanced chronic kidney disease (CKD), we are committed to filling a critical treatment gap for patients at the highest risk of kidney failure where their only options are dialysis or kidney transplant.
Our work is grounded in compassion for the profound challenges of the kidney disease journey. We are driven by a clear purpose: to bring hope, stability, and meaningful change to patients and their families. Every step we take reflects our belief in the transformative potential of our breakthrough therapeutic platform.
